480 related articles for article (PubMed ID: 33359211)
1. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs.
Chen C; Xie L; Ren T; Huang Y; Xu J; Guo W
Cancer Lett; 2021 Mar; 500():1-10. PubMed ID: 33359211
[TBL] [Abstract][Full Text] [Related]
2. Profiles of immune cell infiltration and immune-related genes in the tumor microenvironment of osteosarcoma cancer.
Liu R; Hu Y; Liu T; Wang Y
BMC Cancer; 2021 Dec; 21(1):1345. PubMed ID: 34922489
[TBL] [Abstract][Full Text] [Related]
3. Osteosarcoma, personalized medicine, and tissue engineering; an overview of overlapping fields of research.
Bozorgi A; Sabouri L
Cancer Treat Res Commun; 2021; 27():100324. PubMed ID: 33517237
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for osteosarcoma: Where do we go from here?
Wedekind MF; Wagner LM; Cripe TP
Pediatr Blood Cancer; 2018 Sep; 65(9):e27227. PubMed ID: 29923370
[TBL] [Abstract][Full Text] [Related]
5. Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
Sundara YT; Kostine M; Cleven AH; Bovée JV; Schilham MW; Cleton-Jansen AM
Cancer Immunol Immunother; 2017 Jan; 66(1):119-128. PubMed ID: 27853827
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the effects of M2 macrophage-derived PDE4C on the prognosis, metastasis and immunotherapy benefit of osteosarcoma.
Pan F; Pan R; Hu R; Zhang H; Lei S; Zhang L; Zhou C; Zeng Z; Tian X; Xie Q
J Cell Mol Med; 2024 May; 28(10):e18395. PubMed ID: 38774995
[TBL] [Abstract][Full Text] [Related]
7. Comparative Immunology and Immunotherapy of Canine Osteosarcoma.
Mason NJ
Adv Exp Med Biol; 2020; 1258():199-221. PubMed ID: 32767244
[TBL] [Abstract][Full Text] [Related]
8. Effects of microenvironment in osteosarcoma on chemoresistance and the promise of immunotherapy as an osteosarcoma therapeutic modality.
Yu L; Zhang J; Li Y
Front Immunol; 2022; 13():871076. PubMed ID: 36311748
[TBL] [Abstract][Full Text] [Related]
9. Current and Emerging Targets in Immunotherapy for Osteosarcoma.
Miwa S; Shirai T; Yamamoto N; Hayashi K; Takeuchi A; Igarashi K; Tsuchiya H
J Oncol; 2019; 2019():7035045. PubMed ID: 30693030
[TBL] [Abstract][Full Text] [Related]
10. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.
Wang SD; Li HY; Li BH; Xie T; Zhu T; Sun LL; Ren HY; Ye ZM
Int Immunopharmacol; 2016 Sep; 38():81-9. PubMed ID: 27258185
[TBL] [Abstract][Full Text] [Related]
11. Osteosarcoma: current status of immunotherapy and future trends (Review).
Mori K; Rédini F; Gouin F; Cherrier B; Heymann D
Oncol Rep; 2006 Mar; 15(3):693-700. PubMed ID: 16465432
[TBL] [Abstract][Full Text] [Related]
12. Application of Long Noncoding RNAs in Osteosarcoma: Biomarkers and Therapeutic Targets.
Li Z; Dou P; Liu T; He S
Cell Physiol Biochem; 2017; 42(4):1407-1419. PubMed ID: 28715796
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
14. Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors.
Ratti C; Botti L; Cancila V; Galvan S; Torselli I; Garofalo C; Manara MC; Bongiovanni L; Valenti CF; Burocchi A; Parenza M; Cappetti B; Sangaletti S; Tripodo C; Scotlandi K; Colombo MP; Chiodoni C
Clin Cancer Res; 2017 Sep; 23(17):5149-5161. PubMed ID: 28600479
[No Abstract] [Full Text] [Related]
15. Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma.
Deng C; Xu Y; Fu J; Zhu X; Chen H; Xu H; Wang G; Song Y; Song G; Lu J; Liu R; Tang Q; Huang W; Wang J
Cancer Sci; 2020 Jun; 111(6):1899-1909. PubMed ID: 32232912
[TBL] [Abstract][Full Text] [Related]
16. Construction of immune-related gene pairs signature to predict the overall survival of osteosarcoma patients.
Li LQ; Zhang LH; Zhang Y; Lu XC; Zhang Y; Liu YK; Khader MA; Jia-Wen ; Tao-Liu ; Li JZ
Aging (Albany NY); 2020 Nov; 12(22):22906-22926. PubMed ID: 33203792
[TBL] [Abstract][Full Text] [Related]
17. T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities.
Wang Z; Li B; Ren Y; Ye Z
Front Immunol; 2016; 7():353. PubMed ID: 27683579
[TBL] [Abstract][Full Text] [Related]
18. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
Weibo P; Zhaoming Y
Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for osteosarcoma.
Yahiro K; Matsumoto Y
Hum Vaccin Immunother; 2021 May; 17(5):1294-1295. PubMed ID: 33356848
[TBL] [Abstract][Full Text] [Related]
20. Novel therapeutic strategies for spinal osteosarcomas.
Anwar MA; El-Baba C; Elnaggar MH; Elkholy YO; Mottawea M; Johar D; Al Shehabi TS; Kobeissy F; Moussalem C; Massaad E; Omeis I; Darwiche N; Eid AH
Semin Cancer Biol; 2020 Aug; 64():83-92. PubMed ID: 31152785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]